Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of … – About Your Online Magazine


Globe Newswire press release content. The AP news team was not involved in its creation.

PRINCETON, NJ, May 4, 2021 (GLOBE NEWSWIRE) – Certara, Inc. (Nasdaq: CERT), the global leader in biosimulation, today announced the launch of its Secondary Intelligence ™ software, the first and only software that quantitatively predicts risk adverse effects and safety problems arising from secondary pharmacology that can prevent the clinical development of a drug.

Safety issues are responsible for approximately a quarter of the wear and tear on candidates in drug development projects. They may arise from intentional or unintentional drug receptor interactions, also known as primary or secondary pharmacology, respectively. The secondary pharmacological profile is increasingly applied by drug developers and assessed by regulators to assess the potential for off-target effects of new drugs. To address secondary pharmacology, researchers typically examine their small molecule compounds against a wide panel of off-target receptors. The challenge is to interpret the readings to understand which receptor interactions will contribute to potential adverse effects on clinical and post-marketing development.

“While drug developers and regulators rely on secondary pharmacology analysis to support critical development decisions, the current process is inefficient, inconsistent and often inaccurate,” said William F. Feehery, Ph.D., CEO of Certara. “With our Secondary Intelligence software, drug developers will be able to make faster and more confident decisions about the go / no go portfolio early in the drug discovery and development process, which will help increase the likelihood of success in clinical trials. ”

Certara’s Secondary Intelligence software is the only software that curates and visualizes secondary pharmacology analyzes to assess safety responsibilities against multiple recipients. It ranks the likelihood of off-target interaction during clinical use to make critical decisions about which compounds to progress or modify.

“We unlock the potential of secondary pharmacology data to provide automated intelligence so that pharmacologists and safety toxicologists can more confidently and consistently predict off-target safety risks associated with their compounds faster and earlier,” said Will Redfern, Ph .D., Vice President of Toxicology and Quantitative Systems Security at Certara. “Secondary Intelligence allows drug developers to lower the risk of their programs with evidence-based secondary pharmacology insights, which could save significant time, cost and resources in the future.”

To learn more about Secondary Intelligence software and consulting services, visit: https://www.certara.com/services/quantitative-systems-toxicology-safety/.

About Certara

Certara accelerates medicines using biosimulation software and technology to transform the discovery and development of traditional medicines. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions and leading regulatory agencies in 61 countries.

Contact Certara
Jieun W. Choe
jieun.choe@certara.com

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media contact:
Elizabeth Tang, Ph.D.
Finn Partners
elizabeth.tang@finnpartners.com



Paula Fonseca